|1.||Atkins, Helen S: 3 articles (07/2010 - 11/2009)|
|2.||Brooks, Timothy J G: 3 articles (07/2010 - 11/2009)|
|3.||Sefton, Armine M: 3 articles (07/2010 - 11/2009)|
|4.||Simpson, Andrew J H: 3 articles (07/2010 - 11/2009)|
|5.||Kenny, Dermot J: 2 articles (07/2010 - 11/2009)|
|6.||Pinilla, I: 2 articles (11/2005 - 11/2003)|
|7.||Bregante, M A: 2 articles (11/2005 - 11/2003)|
|8.||Solans, C: 2 articles (11/2005 - 11/2003)|
|9.||Honrubia, F M: 2 articles (11/2005 - 11/2003)|
|10.||Forrest, A: 2 articles (11/2000 - 03/2000)|
01/01/1997 - "Grepafloxacin also appears to be highly effective against extragenital infections."
09/01/1992 - "aureus were 1:2. These data would suggest that an 800-mg dose of OPC-17116 taken orally once daily would provide adequate concentrations to treat infections due to the pathogens examined in this study."
06/01/2004 - "The activity of grepafloxacin in two murine models of Mycobacterium avium infection."
09/01/2003 - "Grepafloxacin potency and spectrum of activity were re-evaluated against contemporary pathogens collected from clinical infections in 2001-2002. "
03/01/2000 - "Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms."
09/01/1997 - "The efficacy and safety of grepafloxacin in treating patients with community-acquired pneumonia (CAP) was assessed in an open-label, noncomparative study. "
09/01/1997 - "Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia."
10/01/1994 - "OPC-17116 showed a greater therapeutic effect than the other drugs against experimental acute pneumonia caused by these organisms in mice or rats. "
09/01/1997 - "Grepafloxacin was highly effective in the treatment of bacterial CAP caused by Streptococcus pneumoniae (irrespective of penicillin susceptibility), Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, and Staphylococcus aureus and in the therapy of atypical pneumonia caused by Mycoplasma pneumoniae and Legionella pneumophila. "
04/01/1999 - "amoxycillin 500 mg. In these studies, grepafloxacin proved effective in the treatment of both typical and atypical pneumonia. "
|3.||Respiratory Tract Infections (Respiratory Tract Infection)
04/01/1999 - "Grepafloxacin is an oral fluoroquinolone, with a microbiological and clinical profile that is particularly suited to the treatment of community-acquired respiratory infections. "
01/01/1999 - "These data support grepafloxacin as a well-tolerated fluoroquinolone suitable for the treatment of community-acquired respiratory tract infections."
12/01/1997 - "Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?"
12/01/1997 - "Grepafloxacin--focus on respiratory infections."
09/01/1997 - "Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. "
|5.||Plague (Bubonic Plague)
|9.||Enoxacin (AT 2266)